sj-docx-1-msj-10.1177_13524585241234783 – Supplemental material for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Supplemental material, sj-docx-1-msj-10.1177_13524585241234783 for Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study by Xavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, Pascal Benkert, Douglas L Arnold, Martin S Weber, Andrea Seitzinger, Hans Guehring, Jamie Shaw, Davorka Tomic, Yann Hyvert, Danielle E Harlow, Martin Dyroff and Jerry S Wolinsky in Multiple Sclerosis Journal</p

Supplementary Appendix, MSJ779952_supplementary_appendix – Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI

<p>Supplementary Appendix, MSJ779952_supplementary_appendix for Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI by Josefina Maranzano, Christine Till, Haz-Edine Assemlal, Vladimir Fonov, Robert Brown, David Araujo, Julia O’Mahony, E Ann Yeh, Amit Bar-Or, Ruth Ann Marrie, Louis Collins, Brenda Banwell, Douglas L Arnold and Sridar Narayanan in Multiple Sclerosis Journal</p

Supplementary Material 1, MSJ779952_supplementary_material_1 – Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI

<p>Supplementary Material 1, MSJ779952_supplementary_material_1 for Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI by Josefina Maranzano, Christine Till, Haz-Edine Assemlal, Vladimir Fonov, Robert Brown, David Araujo, Julia O’Mahony, E Ann Yeh, Amit Bar-Or, Ruth Ann Marrie, Louis Collins, Brenda Banwell, Douglas L Arnold and Sridar Narayanan in Multiple Sclerosis Journal</p

MSJ789884_CONSORT_checklist – Supplemental material for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

<p>Supplemental material, MSJ789884_CONSORT_checklist for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study by Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, Amit Bar-Or, Krzysztof W Selmaj, Lawrence Steinman, Eva K Havrdová, Bruce AC Cree, Xavier Montalbán, Hans-Peter Hartung, Vivian Huang, Paul Frohna, Brett E Skolnick and Ludwig Kappos in Multiple Sclerosis Journal</p

Supplemental material for No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

<p>Supplemental material for No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a by Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser and Gavin Giovannoni in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p

MSJ789884_data_supplement – Supplemental material for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

<p>Supplemental material, MSJ789884_data_supplement for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study by Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, Amit Bar-Or, Krzysztof W Selmaj, Lawrence Steinman, Eva K Havrdová, Bruce AC Cree, Xavier Montalbán, Hans-Peter Hartung, Vivian Huang, Paul Frohna, Brett E Skolnick and Ludwig Kappos in Multiple Sclerosis Journal</p

MSJ789884_supplementary_appendix – Supplemental material for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

<p>Supplemental material, MSJ789884_supplementary_appendix for Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study by Jeffrey A Cohen, Giancarlo Comi, Douglas L Arnold, Amit Bar-Or, Krzysztof W Selmaj, Lawrence Steinman, Eva K Havrdová, Bruce AC Cree, Xavier Montalbán, Hans-Peter Hartung, Vivian Huang, Paul Frohna, Brett E Skolnick and Ludwig Kappos in Multiple Sclerosis Journal</p